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Renal disease is often accompanied by urinary loss of proteins. When this
loss of proteins exceeds the arbitrary value of 3 to 5 grams per day, in the presence
of decreased levels of serum albumin, increased serum cholesterol and edema, one
defines this clinical entity as nephrotic syndrome. Causes of nephrotic syndrome are
diverse. A commonly used classification is the dichotomy into the idiopathic type,
in which the nephrotic syndrome is caused by primary glomerular disease (for
instance membranous glomerulopathy or focal glomerulosclerosis), versus the
secondary type. The latter type of nephrotic syndrome is caused by a specific
etiologic event, or arises as a complication of another disease, such as diabetes
melli 'us (Table 1, chapter 1).
The nephrotic patient is at risk for several complications. Occasionally,
edema can be severe and associated with accumulation of peritoneal or pleural fluid.
Prolonged, massive proteinuria may lead to a negative nitrogen balance and protein-
calorie malnutrition. Transport proteins, trace elements and hormones are lost in the
urine, causing specific deficiency states. Thromboembolic complications form
another threat. The incidence of thromboembolisms has been estimated aÍ"
approximately 357o (l). Furthermore, increased susceptibility for bacterial infections
has been described (2). Perhaps the most contentious area of risk has been the
possible danger of accelerated vascular disease. Although the lipid profile in
nephrotic syndrome is generally considered to be atherogenic (3,4), conclusive
evidence for increased cardiovascular morbidity has been lacking. A recent study
however, showed clearly that the nephrotic syndrome is associated with a high
incidence of coronary heart disease (5). Besides systemic vessels, the renal
vasculature is at risk. Renal function deteriorates in many patients with nephrotic
syndrome, irrespective of the type of the underlying renal disease, and irrespective
of the presence of renal disease activity (6,7).Taking into account the number and
the severity of these possible complications, it is clear that treatment of the
nephrotic syndrome is mandatory.
TREATMENT OF NEPHROTIC SYNDROME
Treatment of the nephrotic syndrome should preferably be curative. In case
of a secondary nephrotic syndrome, one should treat the underlying disease.
However, in many cases such curative treatment is not available or not successful.
In case of idiopathic nephrotic syndrome, treatment with cytotoxic and immuno-
modulating agents is sometimes indicated. In many forms of the idiopathic
nephrotic syndrome, however, the therapeutic effect of these agents is small, or does
not outweigh the possible adverse effects. Membranous nephropathy for instance, is
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described to react favorably to combinations of prednisone and chlorambucil or
cyclophosphamide (8,9). The natural course of this disease entity is, however, in
general benign. It is therefore at least questionable whether all patients should be
treated with immunosuppressive drugs that are known to cause many side-effects
(10). These considerations have led to a quest for treatment strategies that primarily
aim at ffeating only the symptoms of nephrotic syndrome. Diuretics are used to
mobilize nephrotic edema, and lipid lowering drugs can ameliorate the disturbances
in lipid profile.
Since proteinuria is the pivotal clinical feature in the nephrotic syndrome,
lowering proteinuria has gained much attention as symptomatic treatment.
Nowadays, several therapeutic options are available for this goal. Unfortunately, the
clinical relevance of these treatment strategies is limited. Although NSAID's are
effective in lowering urinary protein excretion, they concomitantly cause gastro-
intestinal discomfort in a high percentage of patients, and may decrease renal
function (11-13). The 207o decrease in proteinuria observed with (reversibly) a low
protein diet or with platelet aggregating inhibitors is not very impressive (14-18,19-
2l), and with cyclosporin nephrotoxicity has been observed, even when prescribed
in low-doses (22,23). Besides these treatment regimens, angiotensin I converting
enzyme (ACE) inhibitors have become available to lower proteinuria.
THE ANTIPROTEINURIC EFFECT OF
ANGIOTENSIN I CONVERTING ENZYME INHIBITORS
ACE-inhibitors were originally developed and introduced into clinical
practice for the management of hypertension. In 1984, it was first described that
ACE inhibitors reduce microalbuminuria (24,25). Shortly thereafter, it was found
that these agents lower urinary protein excretion also in patients with nephrotic
range proteinuria (26,27). Many experimental and clinical trials were started since,




Because ACE inhibitors lower blood pressure, it was assumed that the fall in
blood pressure played a role in the antiproteinuric effect. In support of this
hypothesis are findings with several other antihypertensives. These showed a similar
decrease in proteinuria as seen with ACE inhibitors (28-30). These observations a.re
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equivocal, since many other investigators mention a less marked effect of
conventional antihypertensives (31-34). To clarify the issue whether ACE inhibitors
differ from other antihypertensives in antiproteinuric efficacy, we performed a meta-
analysis of articles published on this issue (chapter 2). In order to minimize
publication bias, only direct comparative trials were included in this analysis. These
were defined as trials that study the effects of ACE inhibitors and another
antihypertensive agent concomitantly, irrespective of the type of design.
Whereas in the 41 identified studies, the blood pressure lowering effect of
ACE-inhibitors equalled that of the other antihypertensives, their antiproteinuric
effect was significantly superior. On average, proteinuria decreased with
approximately 4O7o on ACE inhibitors, compared to an approximately 2O7o decrease
with "non-ACEi" antihypertensives. These findings indicate that ACE inhibitors
confer a beneficial effect on proteinuria above that solely attributable to their blood
pressure lowering effect. The antiproteinuric effect of ACE inhibition in these
studies was found to be quite uniform, whereas with other antihypertensives a much
greater interstudy variability was observed. Multiple variable regression analysis
revealed that the class of the "non-ACEi" antihypertensive agent was of no
importance: beta-blockers and calcium channel antagonists show a similar poor
response. Within the class of calcium channel antagonists however, considerable
differences were found, with nifedipine having the least effect. Furthermore, it was
shown that the influence of blood pressure reduction to determine an antiproteinuric
response in diabetic patients is not greater than in non-diabetics. It is important
though, to emphasize that this thesis and review focus primarily on the effects of
ACE inhibition in non-diabetic renal diseases.
Renal hemodynamics
Assuming that the antiproteinuric effect of ACE inhibitors cannot be
attributed completely to the fall in systemic blood pressure, what other mechanism
may explain the antiproteinuric capacity of this class of drugs? The prevailing
hypothesis, predominately derived from animal studies, suggests a relation between
the reduction in proteinuria and ACE inhibition induced changes in renal
hemodynamics. Micropuncture studies indicated that ACE inhibitors cause a
predominantly postglomerular vasodilation, resulting in a decrease in intra-
glomerular pressure (35,36). The decrease in intraglomerular pressure in turn is
assumed to result in a decrease in proteinuria. Clinical studies showed a renal
hemodynamic profile of ACE inhibition that may be in accordance with these
experimental data. Glomerular filtration rate remains stable or is slightly reduced,
and effective renal plasma flow rises (37). This response pattern is suggestive for
postglomerular vasodilation. Several clinical studies found the antiproteinuric effect
of ACE inhibition iÍ
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of ACE inhibition indeed to coincide and correlate with the changes in renal
hemodynamics (38,39). Indirect evidence for the role of renal hemodynamic
parameters can be derived from studies that combined various antiproteinuric
treatment srategies. NSAID's and low protein diets have been claimed to cause
afferent vasoconstriction. One would therefore expect that when these treatments are
prescribed concomitantly with an agent that causes efferent vasodilation, such as an
ACE inhibitor, a further decrease in proteinuria may be obtained compared to single
treatment. Indeed, such an additive antiproteinuric effect treatment has been found,
both for the combination of ACE inhibition with an NSAID (40,41), as well for the
combination ACE inhibition with a low protein diet (chapter 5)
The assumed direct causal relationship between the changes in renal
hemodynamics induced by ACE inhibition and their antiproteinuric effect may
however, be questioned. First, the maximum antiproteinuric response to ACE
inhibition is reached only three to four weeks after initiation of therapy, whereas the
renal hemodynamic effects are maximal within hours, and remain relatively stable
at this level (chapter 3). Second, Heeg et al showed that systemic infusion of
angiotensin II in proteinuric patients treated with long-term ACE inhibition did
offset the renal hemodynamic effects induced by this treatment, whereas the
antiproteinuric effect was not affected (42). Both observations contradict a direct
relation between ACE inhibition induced changes in renal hemodynamics and the
antiproteinuric effect.
Glomerular hypertrophy
Another pharmacodynamic mechanism that may explain the antiproteinuric of
ACE inhibitors has been postulated by the group of Ichikawa et al. According to
their theory, after an initial nephron loss, the remnant glomeruli are exposed to
increased quantities of growth promoting factors (43-45). These are said to be self-
inflictive in nature due to their capacity to stimulate the production of excessive
amounts of extracellular matrix in the mesangial area. When the excessive matrix
oblíterates the glomerular capilíary lumen, a typrcal scleronc lesloÍl appeaÍs. -(ÍÍts ts
thought to result in a vicious and accelerating process, since sclerosis induces
further reduction in the nephron population, thereby imposing greater influence of
growth-promoting factors even on glomeruli that were initially resistant. In their
opinion antihypertensive drugs exert their antiproteinuric and antisclerotic actions
through mechanism(s) independent of their modulatory role on glomerular pressure,
but primarily by reducing glomerular hypertrophy. Interestingly, angiotensin II has
been shown to be a potent renal growth factor ín-vítro (46). This observation might
welt fit this hypothesis, since decreased formation of angiotensin II during ACE
inhibition may thus be expected to result in decreased glomerular hypertrophy.
- I4 l -
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Unification?
Advocates of the two above mentioned mechanisms that may explain the
antiproteinuric efficacy of ACE inhibitors, that is changes in renal hemodynamics
versus changes in glomerular growth processes, opposed for a long time. Evidence
protrudes that may unify both theories. Gibbons and Dzau recently reviewed the
emerging concept of so-called vascular remodeling (47). Vascular remodeling is
supposed to be an active process of sffuctural alteration, which is dependent on a
dynamic interaction between hemodynamic stimuli and locally generated growth
factors and vasoactive substances. In their opinion, "remodeling" is primarily a
beneficial adaptive proces that occurs in response to long-term changes in
hemodynamic conditions, but it may subsequently contribute to the pathophysiology
of vascular diseases and circulatory disorders. The pathways mediating the response
of endothelial cells to hemodynamic stimuli are poorly understood, but
electrophysiologic studies show that pressure and tension stimulate cationic channels
(48,49), and activate a genetic program that alters the balance of the mediators of
remodeling, by activating the transcription of genes for factors such as nitric oxide
synthetase and platelet derived growth factor (50,51). Stretch and tension are thus
hypothesized to alter vasculatur structure, as well as tone.
Indications, albeit indirect, that vascular remodeling may be important for the
specific changes in the glomerular vasculature induced by ACE inhibition have been
provided recently. In-vitro it has been described by Coers et al that hydrostatic
pressure alters the differentiation of glomerular visceral epithelial cells (52). It has
furthermore been shown that the application of stretch increases mesangial cell
proliferation and collagen synthesis (53), possibly mediated by induction of certain
genes (54). A role for the renin-angiotensin system has been suggested by the
finding that angiotensin II increased the hyperproliferative response to mechanical
strain (55). Riser et al showed ex-vívo that glomerular hypertension provokes
increased extracellular matrix production (56), whereas Rosenberg and Hostetter
found ín-vít,o that intrarenal vasoconstriction due to angiotensin II is associated with
expression of early growth response genes (57). Considering these findings, it may
well be that ACE inhibition causes a decrease in intraglomerular pressure, which in
turn induce changes in glomerular growth processes that alter the structure of the
glomerular barrier. Ultimately, this leads to the decrease in proteinuria observed
with these agents. In this concept the aforementioned theories that may explain the
antiproteinuric response to ACE inhibitors ('renal hemodynamics' versus
'glomerular hypertrophy') are not opposing, but reflect successive events in a
common sequence. It could of course also be that both events occur concomitantly.
That alterations in glomerular structure and function are the result of changes in
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In experimental renal disease, infusion of angiotensin II was proven to induce
renal vasoconstriction and an increase in proteinuria, effects opposite to those of
ACE inhibition (58-61). It was therefore assumed that the renal effects of ACE
inhibitors are the result of inhibition of angiotensin II formation. However, the
angiotensin I converting enzyme has been shown to be identical to kininase II, the
enzyme that breaks down, amongst others, bradykinin (62). ACE inhibition is
therefore hypothesized to result not only in a decreased production of the
vasoconstrictor hormone angiotensin II, but also in accumulation of the vasodilator
hormone bradykinin. A number of animal studies suggest that bradykinin-related
effects may indeed contribute to the renal effects of ACE inhibitors (63-69). The
above mentioned study from Heeg et al, in which exogenous angiotensin II could
not abolish the antiproteinuric effect of ACE inhibition, also questions the central
role of angiotensin II in the proteinuria lowering effect of these agents (42).Lastly,
it is puzzling that during chronic ACE inhibition systemic angiotensin II levels
increase towards pretreatment levels, whereas the effects of ACE inhibition are still
present (70, chapter 3).
To resolve the question whether or not the effects of ACE inhibition are
angiotensin II related, we performed a study in which the effects of an ACE
inhibitor were compared to those of the angiotensin II antagonist losartan (chapter
4). This latter compound blocks specifically angiotensin II receptors and it has no
effect on the kinin-kallikrein system (71). It was found that the angiotensin II
antagonist induces changes in blood pressure, renal hemodynamics and urinary
protein excretion that are qualitatively and quantitatively similar to those observed
with an ACE inhibitor. The strikingly similar response on both agents suggests that
ACE inhibitor induced effects are primarily mediated by the inhibition of
angiotensin II activity, and not by interference in the kinin-kallikrein system.
BENEFITS
After it was first recognized that ACE inhibitors may effectively reduce
proteinuria, many studies were started to confirm this effect. Most of these studies
focussed either on the short-term effects of such fieatment, or long-term effects
were studied in hypertensive patients with mild proteinuria. Important questions
remained therefore unanswered for a relatively long time, such as whether the
antiproteinuric effect of ACE, inhibition in patients with nephrotic syndrome is
maintained during long-term treatment, and whether the reduction in proteinuria by
ACE inhibition results in amelioration of other symptoms and complications of the
nephrotic syndrome, including the progressive loss of renal function. These and




ACE inhibition generally lowers urinary protein loss with approximately
407o. Unfortunately, ACE inhibitors are not equally efficacious in every patient.
Part of the variation in the antiproteinuric response to ACE inhibition may be
explained by patient related factors, whereas also drug-related factors are important.
With regard to patient related factors, meta-analyses suggest that neither
baseline renal function, nor baseline proteinuria or type of renal disease seem to
determine the antiproteinuric response to ACE inhibition (72,73, chapter 2). Activa-
tion of the renin angiotensin system however, seems to be a prerequisite; it has been
shown that whereas patients on a sodium resficted diet (50 to 100 mmol per day)
experienced a 507o fall in protein excretion during short-term ACE inhibition, an
increase in sodium intake to 200 mmol per day nearly abolished the antiproteinuric
effect (74). In a recent study we even found that during prolonged ACE inhibitor
treatment a single high urinary sodium measurement is often accompanied by a
reduced antiproteinuric response in that patient (chapter 6). It is thus important for
an ACE inhibitor to be optimally effective that the renin angiotensin system is
activated. This can be done by mobilizing edema, restricting dietary sodium and/or
co-prescribing diuretics.
V/ith regard to drug-related factors, there appear to be no differences between
the various ACE inhibitors in their antiproteinuric efficacy (72,73, chapter 2),
whereas the dose of the ACE inhibitor, as to be expected, is impoÍtant (74, chapter
4). One should furthermore be aware of the fact that the antiproteinuric effect has a
slow onset. The maximum antiproteinuric effect occuÍs only several weeks after
start of ffeatment (chapter 3), whereafter it remains stable (chapter 6). One should
therefore not be disappointed when after one to two weeks ACE inhibitor treatment
only limited success in decreasing proteinuria is observed.
Even when all above mentioned conditions are met, the clinician may
conclude that the antiproteinuric effect of ACE inhibitors is not sufficient to
satisfactorily treat the individual patient with nephrotic syndrome. Interest has
therefore risen in combinations of various antiproteinuric freatment strategies. Heeg
et al demonstrated that indomethacin and lisinopril induce such an additional
proteinuria lowering effect (40). The clinical use of this specific combination is
however, limited because of potential side-effects, such as a rise in serum potassium
and a fall in glomerular filtration rate. We therefore performed a study in which we
questioned whether another combination, being an ACE inhibitor and a low protein
diet, would have a similar additive value at a more favorable side-effect profile
(chapter 5). It was found that single treatment with enalapril or a low protein diet
lowered urinary protein excretion. The antiproteinuric effect of the low protein diet
was markedly less than that of ACE inhibition. However, not all patients were able
to adhere to the prescribed 507o decrease in protein intake during the low protein
diet. Since the decrease in dietary protein intake was found to correlate with the
decrease in Proteinuria,
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Review and summary
decrease in proteinuria, better compliance to the prescribed low protein diet is
expected to result in a greater decrease in proteinuria. Most importantly, the
combination of both regimens was found to lower proteinuria significantly more
than single treatment. Besides the obvious implications for symptomatic treatment
of patients with nephrotic syndrome, the combination of a low protein diet and an
ACE inhibitors of specific interest because both regimens have been claimed to
retard renal function deterioration (75-77). Whether there will also be an additive
renoprotective effect has yet to be elucidated.
Serum albumin
Although hypoalbuminemia is one of the defining signs of nephrotic
syndrome, its possible role in causing morbidity and mortality in proteinuric patients
has earned only little attention. In a wide variety of other clinical settings however,
hypoalbuminemia has been shown to be a reliable prognostic indicator for mortality,
length of hospital stay, and complication rate (78). In an editorial Marik et al
explain that it has been postulated that the low albumin concentration per se is
responsible for the increased morbidity, and that hypoalbuminemic patients have
been treated with exogenous albumin in the hope that their outcome would be
improved (79). In contrast, others regard hypoalbuminemia as a "normal"
phenomenon in the critically ill patient, the degree of hypoalbuminemia merely
reflecting the severity of illness (79). Anyway, in nephrotic patients it is hypoal-
buminemia that conffibutes to the occurrence of edema. Increasing serum albumin
concentration is therefore an important therapeutic goal in these patients. As
expected, serum albumin concentration raises over time during long-term an-
tiproteinuric treatment with ACE, inhibition, the increase in albumin being correlated
with the antiproteinuric response (chapter ó). Maximum values for serum albumin
are reached only after several months of treatment (chapter 6). Similar increases in
serum albumin have been obtained with NSAID therapy (chapter 7), whereas a low
protein diet had no effect on albumin mass despite a fall in urinary protein loss
(chapter 5). The failure to improve hypoalbuminemia during a low protein diet is
possibly caused by a concomitant decrease in albumin synthesis rate (14,80).
Serum cholesterol
Hyperlipidemia is another well recognized characteristic of the nephrotic
syndrome. Increases in serum total cholesterol, VLDL and LDL cholesterol, and
triglycerides are common features of this form of hyperlipidemia (3,81, chapter 8,
chapter 9). Recent studies have shown that also lipoprotein (a) is elevated (82-84,
chapter 9). This lipoprotein is said to be another independent riskfactor for
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atherosclerosis and thrombosis (85,86). The lipoprotein profile in nephrotic
syndrome may thus be considered to be highly atherogenic. It has however, been a
matter of debate for a long time whether these abnormalities should be treated.
Because of the low incidence of nephrotic syndrome, and the difficulty of obtaining
sufficiently long-term follow-up, it has been difficult to assess whether the
cardiovascular risk profile is indeed disadvantageous in this specific patient
population. A turn in this debate can be observed. Ordonez et al provided the long-
awaited data (5). They showed in a population of 142 patients with nephrotic-range
proteinuria, that the incidence of cardiovascular morbidity and mortality was three-
to fivefold increased during a follow-up period of more than five years. From these
data, it might be inferred that treatment of the hyperlipidemia of nephrotic
syndrome is desirable.
Attempts to lower cholesterol have been made with various therapeutic
modalities. Cholesterol low diets have been proven to be of limited value, as were
lipid lowering drugs like clofibrate and bile acid binders. Only one class of lipid
lowering drugs has been shown to be clinically effective: HMG-CoA reductase
inhibitors lower cholesterol with approximately 307o (87-89). Interestingly, initial
pilot studies showed that HMG CoA reductase inhibitors also reduced proteinuria
(90). This finding drew great attention, because it suggests that hyper-
cholesterolemia may have a role in the pathophysiology of renal disease. However,
follow-up studies of the same group, as well as a study of Thomas et al could not
confirm this (88). With respect to lipoprotein (a), it was found that HMG-CoA
reductase inhibitors do not lower the increased levels of this lipoprotein (91).
Little is known about the effects of symptomatic antiproteinuric therapy on
the derangements in lipoprotein profile. We therefore studied patients with nephrotic
range proteinuria both before and after various forms of antiproteinuric treatment
(chapter 9). It was found that a decrease in proteinuria was associated with a fall in
serum total and LDL+VLDL cholesterol, and even with a fall in Lp(a)
concentration. These effects were most pronounced when a combination of
antiproteinuric treatment strategies was given, suggesting that these effects were
related to the changes in proteinuria and independent of the type of antiproteinuric
treatment given. It should be emphasized that normalization of the lipoprotein
profile generally does not occur. The mean percentage decrease in cholesterol
amounts approximately l07o during single treatment with either ACE inhibition,
NSAID's or a low protein diet (84, chapters 7-9). However, when two of these
antiproteinuric treatment regimes were combined, and consequently a further
decrease in proteinuria occurs, a clinically significant effect was obtained.
Cholesterol was now lowered with percentages around 207o, whereas Lp(a) even
fell with 407o (chapters 5 and 9). Antiproteinuric treatment, by means of
improving the derangements in lipid profile, may thus exert a beneficial effect on
the increased risk for thrombosis and atherosclerosis observed in nephrotic patients.
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The mechanism why there is an abnormal lipoprotein profile in nephrotic
syndrome is poorly understood (4). Increased hepatic lipoprotein production, as well
as defective catabolism have been implicated. Among other pathways, the processes
of cholesteryl ester formation and transfer are of importance in the intravascular
metabolism of lipoproteins. A major proportion of cholesteryl ester in plasma is
generated through the esterification of free cholesterol by the action of
lecithin:cholesterol acylransferase (LCAT), HDL being the preferred substrate.
Subsequently, cholesteryl ester is transferred toward apolipoprotein B-containing
lipoproteins by the action of cholesteryl ester ffansfer protein (CETP). Little
information is available on possible alterations in LCAT and CETP in relation to
glomerular proteinuria. We therefore studied LCAT and CETP activities in
proteinuric patients both before, during and after antiproteinuric treatment with ACE
inhibition (chapter 8). Both LCAT and CETP activities were found to be inversely
correlated with serum albumin, and the activity of LCAT decreased concomitantly
with a fall in proteinuria during ACE inhibition therapy. This suggests that
increased activities of LCAT and CETP may indeed play a role in causing or
aggravating the lipoprotein abnormalities in glomerular proteinuria.
Renal function
Once renal function is compromised, which is often the case in nephrotic
patients, a steady progressive fall of glomerular filration rate is often observed (89).
This phenomenon appears not to be related to the initial cause of renal failure, and
may occur despite the fact that disease activity is absent. Although the chapter on
elucidating the mechanism(s) involved in this progression has certainly not been
closed, several factors appear to be involved.
First of all, it was soon recognized that hypertension plays an important role.
Patients with lower blood pressure progress significantly slower than patients with
higher blood pressure, and antihypertensive treatment may slow the progression (93-
95). Secondly, the increased pressure in the remaining glomeruli, occurring as a
result of a functional hemodynamic adaptation to the reduced number of nephrons,
may be involved. The increased intraglomerular pressure is thought to damage the
residual nephrons, resulting in a vicious circle. Indeed, lowering of intraglomerular
pressure appeared to prevent the detrimental effects on renal function and histology
(96). Besides these two pressure related phenomena other factors may be relevant.
Keane et al point to the role of lipids (97). Others mention the inflictive nature of
growth promoting factors (43-45), and Remuzzi and Bertani recently reviewed the
putative role of glomerular protein leakage (98). They convincingly argue that
proteinuria plays a key role in the progression or renal function deterioration. In
patients with renal disease of diverse etiologies proteinuria has indeed been shown
to correlate with the rate of renal function deterioratton (6,7,77).
-153-
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Whatever the true mechanism for progressive renal function loss may be,
interventions causing a reduction in either of the above risk factors may be of use
in protecting a patient with renal disease against further deterioration. There is
ample evidence that many of the new drugs that became recently available for
treatment of hypertension are equally effective in lowering blood pressure in
patients with renal disease. However, distinct differences may be observed between
these antihypertensives as far as other risk factors are concerned. With respect to
ACE inhibitors, these agents inhibit the formation of angiotensin II which hormone
constricts besides systemic vasculature also the renal vasculature, predominantly at
the site of the efferent arteriole (59-61). Consequently, ACE inhibitors lower
intraglomerular pressure substantially more than other antihypertensives (96).
Angiotensin II has furthermore been hypothesized to act as growth-promoting factor
on glomerular level (46). With respect to proteinuria, it has become clear that ACE
inhibitors have greater antiproteinuric efficacy than most other antihypertensives
(72,73, chapter 2). lt is moreover intriguing that we, and others, found that patients
with the most marked antiproteinuric response to ACE inhibition, and tl-re patients
with the lowest amount of proteinuria during treatment, show the least progression
of renal function deterioration (99-101, chapter 6). From the currently available
data one may thus conclude that ACE-inhibitors may have additional effects above
blood pressure lowering alone.
In view of these theoretical considerations. one wonders whether there is
clinical evidence showing that ACE inhibitors are superior to other antihyperten-
sives in halting the progression of renal function loss. The results of the first
double-blinded, prospective, randomized trials on this issue have recently become
available. The largest study hitherto has been performed by Lewis and coworkers in
patients with diabetic renal disease (102). It showed that significantly less patients
doubled their serum creatinine when treated with captopril, compared to patients
treated with conventional antihypertensives. Unfortunately, blood pressure was
lower in the captopril group. The authors claim however, based on subgroup
analysis and evaluation of the data after adjustment for blood pressure, tl'rat
captopril is more effective in preserving renal function than blood pressure control
alone. In non-diabetic renal disease, Mann et al found retrospectively a significant
slower progression rate in the group treated with an ACE-inhibitor compared to the
conventionally treated group, despite equal blood pressure control (103). In studies
in which patients were first treated with conventional antihypertensives followed by
a period of ACE-inhibitor therapy, either added or alone, the ACE-inhibitor
appeared to slow the progression compared to the previous treatment period
(33,104-107). However, the evidence'for this conclusion remains rather thin, and
more studies are clearly required. Certainly, studies on the different calcium-channel
blockers are needed, since some may also be renal protective, maybe via a different
mechanism than ACE-inhibitors (108,109).
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LIMITATIONS TO THE USB OF ACE INHIBITION
The foregoing may give rise to the impression that the use of ACE, inhibitors
in patients with nephrotic syndrome is associated with sheer benefits. We have to be
aware, however, that the "hurrah-curve" has also a down-slope in the form of
adverse effects. The most well-known side-effect is cough. This occurs in 5 to l57o
of the patients, depending on the study population (110). Fortunately, the intensity
of this symptom is generally rated mild to moderate, and only in few cases
treatment has to be withdrawn. Furthermore, hyperkalemia may occur, especially in
patients with compromised renal function. It is possible to co-prescribe potassium-
loosing loopdiuretics to minimize this problem. Far less frequent, but of potential
greater danger, is the occurrence of angioneurotic edema. Edema of tongue, glottis
or larynx can induce airway obstruction that may have fatal outcome (110). The
occuÍrence of both cough and angioneurotic edema are thought to be mediated by
the interference of ACE inhibitors in the bradykinin system (lll). Perhaps that
angiotensin II antagonists, by virtue of their greater specificity for the renin
angiotensin system, may prove to be of clinical benefit by having a more favorable
side-effect profile.
Less well-known are the detrimental effects of ACE inhibitors in pregnancy.
These have recently been reviewed by Shotan et al (II2). Their article mentions
experimental data and case-reports on humans that consistently showed a certain
degree of morbidity and mortality in fetuses and newborns that were exposed in
utero to ACE inhibitors. These disorders are thought to be related to pharmacologi-
cal activity of these drugs in the second and third trimester of pregnancy, rather
than due to a teratogenic effect. It seems therefore reasonably safe to prescribe ACE
inhibitors to female patients of child-bearing potential. However, in case of a
possible pregnancy, or the wish for children, ACE inhibitors should be discontinued,
and female patients should be warned for these effects before treatment is started.
Other side effects of ACE inhibitors in patients with nephrotic syndrome are
related to their mechanism of action. A large proportion of the patients with
nephrotic syndrome is normotensive, and although ACE inhibition is now prescribed
because of its antiproteinuric efficacy, a decrease in blood pressure cannot be
avoided. The fall in blood pressure is however, generally well tolerated, but in-
cidently, it may result in hypotensive complaints. The renal hemodynamic profile,
characteristic for ACE inhibitors, may also turn into a handicap. Especially in
disease states with decreased renal blood flow, such as stenosis of the renal artery,
heart failure, or the use of diuretics, the postglomerular vasodilation induced by
ACE inhibition may result in a considerable decrease in glomerular filration rate. In
these situations the dose of the ACE inhibitors should be tempered in combination
with "sodium repleting" action, whereafter the fall in renal function may resolve.
ACE inhibitors thus certainly possess negative qualities. The nature and intensity of
their side effects however, makes that these drugs compare favorably to other




Of the questions we had at the time we started our investigations four years
ago, a number are not resolved. It remains unknown whether ACE inhibitors lower
proteinuria by changes in the glomerular basement membrane that Íue caused in-
directly by changes in renal hemodynamics or directly by diminished activity of
angiotensin II as a growth factors. Clinical studies that compare the antiproteinuric
effect of ACE inhibitors to that of other agents that have a similar renal
hemodynamic profile, but that do not interfere with the renin angiotensin system,
may resolve this issue. Important from a clinician's point of view are furthermore
the questions "which patients to treat", and "at which dose".
With regard to question which patients to treat, it is important to note that
almost every trial that studied the effects of ACE inhibitors in nephrotic syndrome
comprised patients with renal disease of various origin. In specific forms of
nephrotic syndrome, it has not yet been established how ACE inhibition compÍIres
to other regimens, either symptomatic or curative. Another issue is that normoten-
sive proteinuric patients are only treated with ACE inhibition, at least in our
department, when their urinary protein loss exceeds the arbitrary value of 3 grams
per day. Now these agents have shown to be relatively safe in use, their use may be
perhaps be expanded to patients with lower levels of proteinuria.
With regard to the dose of ACE inhibition to be used, when one assumes that
the long-term renoprotective ffect of ACE inhibition is primarily mediated by their
anti-trophic effects, it may well be that low-dose ACE inhibition will be sufficient.
Evidence for this hypothesis can be derived from studies in diabetic renal disease
that prescribed ACE inhibition aÍ such low doses that blood pressure did not
change. However, glomerular basement membrane characteristics did improve, and
microalbuminuria decreased (113,114). In non-diabetic renal disease however, the
situation seems different. A positive dose-effect relation has been found between the
dose of the ACE inhibitor and the antiproteinuric response obtained (74).Long-term
renal function outcome during ACE inhibition has furtheÍïnore been found to be
correlated with the change in proteinuria induced by this treatment, and with the
amount of urinary protein loss that remained. Although these data do not necessarily
imply a cause-effect relation, it seems advisable to titrate an ACE, inhibitor to a
dose that induces a maximal antiproteinuric effect.
Although this last paragraph indicates that there are many questions left, one
cannot than conclude that the knowledge on mechanism and benefits of the
antiproteinuric effect of ACE inhibition is expanding rapidly. I hope that the studies
presented in this thesis may have provided a modest contribution to this progress.
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